{
    "symbol": "OPGN",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-11 23:03:07",
    "content": " I encourage you to review OpGen's filings with the Securities and Exchange Commission, including, without limitation, the Company\u00e2\u0080\u0099s most recent Form 10-K and form 10-Q for the second quarter and the first half of 2022 that will be filed with the SEC, which will identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Factors that may affect the Company\u00e2\u0080\u0099s results include, but are not limited to, the success of the Company\u00e2\u0080\u0099s commercialization efforts and partnering strategies; its ability to successfully, timely, and cost-effectively develop, seek, and obtain regulatory clearance for and commercialize its product and service offerings; the Company\u00e2\u0080\u0099s ability to continue to successfully achieve the expected synergies from the Company\u00e2\u0080\u0099s completed business combination with Curetis and to implement its commercial strategy; the impact of the continuing global COVID-19 pandemic on the Company\u00e2\u0080\u0099s business and operations and on capital markets and general economic conditions; the Company\u00e2\u0080\u0099s use of proceeds from recent financings, as well as its ability to access additional financing in the future; the Company\u00e2\u0080\u0099s ability to satisfy debt obligations under its loan with the European Investment Bank; the rate of adoption of its products and services by hospitals and other healthcare providers in general, as well as during the current COVID-19 pandemic, and geopolitical situation, in particular; the effect of the military action in Russia and Ukraine on its distributors, collaborators, and service providers; the effect on the Company\u00e2\u0080\u0099s business of existing and new regulatory requirements; and other economic and competitive factors. We closed out the second quarter with approximately $967,000 of revenue, a 19% increase from this time last year, while revenue in the first half of 2022 added up to $1.4 million compared to $1.6 million in the six months period of 2021. In addition to increasing our revenue, we also decreased our operating expenses for the three months ending June 30, 2022, by almost 10% to $6.2 million compared to nearly $7 million in the second quarter of 2021. For the first half of 2022, we saw a decrease by more than 10% in operating expenses from $14 million in the six months of 2021 to $12.6 million in the comparable period this year. Our second quarter 2022 R&D expenses were $2.3 million compared to $2.9 million in Q2 of 2021, a 20% reduction. Second quarter 2022 G&A expenses were $2.1 million, down by about 22% from our Q2 2021 G&A expenses of $2.7 million. In the first half of 2022, G&A expenses amounted to $4.8 million, which corresponds to a decrease of about 11% from $5.4 million in the first half of the previous year. Second quarter and first half 2022 sales and marketing expenses were $1.2 million and $2.2 million respectively, compared to $800,000 during the second quarter of 2021 and $1.7 million in the first half of 2021. Our net loss available to common stockholders in the second quarter of 2022 was $5.8 million or $0.13 per share, which is substantially lower than $7.1 million or $0.19 per share in the second quarter of 2021."
}